Experts highlight the future of heart failure management.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD.
When asked about the future of heart failure management, Desai says he is excited about better phenotyping beyond ejection fraction to personalize care. Groves notes this complexity reinforces the need for collaborative, integrative care models. Albert looks forward to disruptive innovations such as devices putting control in patients’ hands, such as glucose monitors for diabetes. Axsom envisions remote monitoring technology empowering self-management. Wright would like research on biomarkers predicting heart failure progression rates to guide treatment intensity. Groves stresses addressing social determinants such as nutrition that influence life outside healthcare visits. Asking where patients shop for food provides insights. In summary, the future of heart failure care involves better phenotyping, disruptive technologies, remote monitoring, risk stratification tools, and addressing social needs, all aimed at optimizing outcomes through individualized, patient-centered care.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More